« Return to News | Drug Sponsors

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

The boards of directors of both companies have unanimously approved the transaction, under which Otsuka will acquire all outstanding Astex shares for $8.50 per share in cash, a 48% premium to the average closing stock price for the prior 30-day period.

Astex is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. Astex has built a myelodysplastic syndromes (MDS) franchise with DACOGEN (decitabine) for Injection. DACOGEN also was approved recently in Europe for the treatment of (elderly) acute myeloid leukemia (AML) in patients over 65 years old. Astex also has five partner-funded programs being developed by Novartis, AstraZeneca, Janssen and through a clinical development partnership with Cancer Research (U.K.).

The acquisition of Astex adds to Otsuka's existing discovery capabilities and pipeline of therapeutic products for neuroscience, cardiovascular and oncology indications, and it provides Otsuka with PYRAMID, a world-class drug discovery platform.

Dr. Taro Iwamoto, Otsuka Pharmaceutical's president and representative director, said, "I hope this acquisition will strengthen not only our cancer portfolio but also our drug discovery research in the central nervous system field, through the acquisition of Astex's fragment-based drug design technology at its Cambridge, England research headquarters and its California clinical oncology R&D department.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.